Skip to main content

Advertisement

SpringerLink
Log in

Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities

  • Non-Thematic Review
  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Estrogen and progesterone receptors (ERs and PRs) are known for their prognostic as well as treatment predictive value in breast cancer. Although these receptors are differentially expressed in some other malignancies, and likely participate in the biology of those cancer types, the relevance to outcome and therapy is not well established. The use of ER as a highly effective therapeutic target in oncology was pioneered in breast cancer, and the lessons learned from its success could potentially benefit patients with several other malignancies in which hormone receptors are highly expressed. Indeed, there are several potent drugs available that target hormone receptors. These agents show incontrovertible evidence of benefit in patients with hormone receptor-positive breast cancer. It is conceivable that these drugs may have salutary effects in a variety of cancers other than those originating in the breast, based on the overexpression of hormone receptors in some patients, and the preclinical and clinical reports showing responses to these drugs in diverse cancers, albeit in small series or anecdotally. We therefore undertook a literature review in order to summarize the current data regarding the biologic and clinical implications of expression of estrogen and progesterone receptors in various malignancies and the possibilities for deployment of hormone manipulation beyond breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Molteni, A., Bahu, R. M., Battifora, H. A., Fors, E. M., Reddy, J. K., Rao, M. S., et al. (1979). Estradiol receptor assays in normal and neoplastic tissues. A possible diagnostic acid for tumor differentiation. Annals of Clinical and Laboratory Science, 9(2), 103–108.

    CAS  PubMed  Google Scholar 

  2. Enmark, E., & Gustafsson, J. A. (1999). Oestrogen receptors—an overview. Journal of Internal Medicine, 246(2), 133–138.

    Article  CAS  PubMed  Google Scholar 

  3. Thornton, M. J. (2002). The biological actions of estrogens on skin. Experimental Dermatology, 11(6), 487–502.

    Article  CAS  PubMed  Google Scholar 

  4. Kumar, S. K., Gupta, N., Rajwanshi, A., Joshi, K., & Singh, G. (2012). Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Cytopathology, 23(3), 181–186. doi:10.1111/j.1365-2303.2011.00853.x.

    Article  CAS  PubMed  Google Scholar 

  5. Thompson, A. M., Jordan, L. B., Quinlan, P., Anderson, E., Skene, A., Dewar, J. A., et al. (2010). Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Research, 12(6), R92. doi:10.1186/bcr2771.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Jensen, E. V., & Jacobson, H. I. (1960). Fate of steroidal estrogens in target tissues. In G. Pincus & E. P. Vollmer (Eds.), Biological activities of steroids in relation to cancer (pp. 161–174). New York: Academic Press.

    Chapter  Google Scholar 

  7. Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., & Shine, J. (1986). Sequence and expression of human estrogen receptor complementary DNA. Science, 231(4742), 1150–1154.

    Article  CAS  PubMed  Google Scholar 

  8. Mosselman, S., Polman, J., & Dijkema, R. (1996). ER beta: identification and characterization of a novel human estrogen receptor. FEBS Letters, 392(1), 49–53.

    Article  CAS  PubMed  Google Scholar 

  9. Chen, G. G., Vlantis, A. C., Zeng, Q., & van Hasselt, C. A. (2008). Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Current Cancer Drug Targets, 8(5), 367–377.

    Article  CAS  PubMed  Google Scholar 

  10. Brandenberger, A. W., Tee, M. K., & Jaffe, R. B. (1998). Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. The Journal of Clinical Endocrinology and Metabolism, 83(3), 1025–1028. doi:10.1210/jcem.83.3.4788.

    CAS  PubMed  Google Scholar 

  11. Bardin, A., Boulle, N., Lazennec, G., Vignon, F., & Pujol, P. (2004). Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer, 11(3), 537–551.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Platet, N., Cathiard, A. M., Gleizes, M., & Garcia, M. (2004). Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Critical Reviews in Oncology/Hematology, 51(1), 55–67. doi:10.1016/j.critrevonc.2004.02.001.

    Article  PubMed  Google Scholar 

  13. Signoretti, S., & Loda, M. (2001). Estrogen receptor beta in prostate cancer: brake pedal or accelerator? The American Journal of Pathology, 159(1), 13–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Leung, Y. K., Lam, H. M., Wu, S., Song, D., Levin, L., Cheng, L., et al. (2010). Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocrine-Related Cancer, 17(3), 675–689. doi:10.1677/ERC-09-0294.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Shaaban, A. M., Green, A. R., Karthik, S., Alizadeh, Y., Hughes, T. A., Harkins, L., et al. (2008). Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clinical Cancer Research, 14(16), 5228–5235. doi:10.1158/1078-0432.CCR-07-4528.

    Article  CAS  PubMed  Google Scholar 

  16. Horwitz, K. B., & Alexander, P. S. (1983). In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology, 113(6), 2195–2201. doi:10.1210/endo-113-6-2195.

    Article  CAS  PubMed  Google Scholar 

  17. O'Malley, B. W., & Schrader, W. T. (1972). Progesterone receptor components: identification of subunits binding to the target-cell genome. Journal of Steroid Biochemistry, 3(3), 617–629.

    Article  PubMed  Google Scholar 

  18. Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L., Gronemeyer, H., et al. (1990). Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. The EMBO Journal, 9(5), 1603–1614.

    PubMed Central  CAS  PubMed  Google Scholar 

  19. Vegeto, E., Shahbaz, M. M., Wen, D. X., Goldman, M. E., O'Malley, B. W., & McDonnell, D. P. (1993). Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Molecular Endocrinology, 7(10), 1244–1255. doi:10.1210/mend.7.10.8264658.

    CAS  PubMed  Google Scholar 

  20. Badve, S., & Nakshatri, H. (2009). Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. Journal of Clinical Pathology, 62(1), 6–12. doi:10.1136/jcp.2008.059899.

    Article  CAS  PubMed  Google Scholar 

  21. Boonyaratanakornkit, V., & Edwards, D. P. (2004). Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones. Essays in Biochemistry, 40, 105–120.

    Article  CAS  PubMed  Google Scholar 

  22. Nasser, S. M., Faquin, W. C., & Dayal, Y. (2003). Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. American Journal of Clinical Pathology, 119(6), 801–806. doi:10.1309/RVTP-1G0Q-727W-JUQD.

    Article  CAS  PubMed  Google Scholar 

  23. Hu, R., Dawood, S., Holmes, M. D., Collins, L. C., Schnitt, S. J., Cole, K., et al. (2011). Androgen receptor expression and breast cancer survival in postmenopausal women. Clinical Cancer Research, 17(7), 1867–1874. doi:10.1158/1078-0432.CCR-10-2021.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Ito, K., Suzuki, T., Akahira, J., Moriya, T., Kaneko, C., Utsunomiya, H., et al. (2002). Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. International Journal of Cancer, 99(5), 652–657. doi:10.1002/ijc.10394.

    Article  CAS  Google Scholar 

  25. Baumgart, J., Nilsson, K., Stavreus Evers, A., Kunovac Kallak, T., Kushnir, M. M., Bergquist, J., et al. (2014). Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients. Climacteric, 17(1), 48–54. doi:10.3109/13697137.2013.800039.

    Article  CAS  PubMed  Google Scholar 

  26. Mobbs, B. G., Johnson, I. E., Connolly, J. G., & Thompson, J. (1983). Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content? Journal of Steroid Biochemistry, 19(3), 1279–1290.

    Article  CAS  PubMed  Google Scholar 

  27. Kumar, A., Klinge, C. M., & Goldstein, R. E. (2010). Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. International Journal of Oncology, 36(5), 1067–1080.

    CAS  PubMed  Google Scholar 

  28. Lee, M. L., Chen, G. G., Vlantis, A. C., Tse, G. M., Leung, B. C., & van Hasselt, C. A. (2005). Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer Journal, 11(2), 113–121.

    Article  CAS  Google Scholar 

  29. Kamat, A., Rajoria, S., George, A., Suriano, R., Shanmugam, A., Megwalu, U., et al. (2011). Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways. Archives of Otolaryngology - Head and Neck Surgery, 137(11), 1146–1153. doi:10.1001/archoto.2011.194.

    Article  PubMed  Google Scholar 

  30. Antico-Arciuch, V. G., Dima, M., Liao, X. H., Refetoff, S., & Di Cristofano, A. (2010). Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene, 29(42), 5678–5686. doi:10.1038/onc.2010.308.

    Article  CAS  PubMed  Google Scholar 

  31. Zeng, Q., Chen, G. G., Vlantis, A. C., & van Hasselt, C. A. (2007). Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Proliferation, 40(6), 921–935. doi:10.1111/j.1365-2184.2007.00471.x.

    Article  CAS  PubMed  Google Scholar 

  32. Tavangar, S. M., Monajemzadeh, M., Larijani, B., & Haghpanah, V. (2007). Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Medical Journal, 48(8), 744–747.

    CAS  PubMed  Google Scholar 

  33. Lewy-Trenda, I. (1998). Estrogen receptors in the malignant and benign neoplasms of the thyroid. Polski Merkuriusz Lekarski, 5(26), 80–83.

    CAS  PubMed  Google Scholar 

  34. Hiasa, Y., Nishioka, H., Kitahori, Y., Yane, K., Nakaoka, S., Ohshima, M., et al. (1993). Immunohistochemical analysis of estrogen receptors in 313 paraffin section cases of human thyroid tissue. Oncology, 50(2), 132–136.

    Article  CAS  PubMed  Google Scholar 

  35. Di Vito, M., De Santis, E., Perrone, G. A., Mari, E., Giordano, M. C., De Antoni, E., et al. (2011). Overexpression of estrogen receptor-alpha in human papillary thyroid carcinomas studied by laser-capture microdissection and molecular biology. Cancer Science, 102(10), 1921–1927. doi:10.1111/j.1349-7006.2011.02017.x.

    Article  PubMed  CAS  Google Scholar 

  36. Vaiman, M., Olevson, Y., Habler, L., Eviatar, E., Zehari, S., Sandbank, J., et al. (2010). The estrogen receptors in the papillary carcinoma of the thyroid gland. Oncology Research, 18(11–12), 537–540.

    PubMed  Google Scholar 

  37. Vaiman, M., Olevson, Y., Habler, L., Kessler, A., Zehavi, S., & Sandbank, J. (2010). Diagnostic value of estrogen receptors in thyroid lesions. Medical Science Monitor, 16(7), BR203–BR207.

    PubMed  Google Scholar 

  38. Ceresini, G., Morganti, S., Graiani, V., Saccani, M., Milli, B., Usberti, E., et al. (2006). Estrogen receptor (ER)-beta, but not ER-alpha, is present in thyroid vessels: immunohistochemical evaluations in multinodular goiter and papillary thyroid carcinoma. Thyroid, 16(12), 1215–1220. doi:10.1089/thy.2006.16.1215.

    Article  CAS  PubMed  Google Scholar 

  39. Vannucchi, G., Perrino, M., Rossi, S., Colombo, C., Vicentini, L., Dazzi, D., et al. (2010). Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. European Journal of Endocrinology, 162(1), 145–151. doi:10.1530/EJE-09-0761.

    Article  CAS  PubMed  Google Scholar 

  40. Kansakar, E., Chang, Y. J., Mehrabi, M., & Mittal, V. (2009). Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer. The American Surgeon, 75(9), 785–789. discussion 789.

    PubMed  Google Scholar 

  41. Memon, G. R., Arain, S. A., Jamal, Q., & Ansari, T. (2005). Immunohistochemical study of progesterone receptors in thyroid gland. The Journal of the Pakistan Medical Association, 55(8), 321–324.

    PubMed  Google Scholar 

  42. Blechet, C., Lecomte, P., De Calan, L., Beutter, P., & Guyetant, S. (2007). Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma. Virchows Archiv, 450(4), 433–439. doi:10.1007/s00428-007-0379-6.

    Article  CAS  PubMed  Google Scholar 

  43. Khalil, A. B., Trudel, M., & Creel, R. (2010). Papillary carcinoma of the thyroid with fibromatosislike stroma: case report and review of literature. Endocrine Practice, 16(4), 650–655. doi:10.4158/EP09061.CR.

    Article  PubMed  Google Scholar 

  44. Kobayashi, S., Tobioka, N., Samoto, T., Tanaka, H., & Masaoka, A. (1982). Studies on the estrogen receptor in human meningioma and thymoma. Nihon Naibunpi Gakkai Zasshi, 58(10), 1333–1340.

    CAS  PubMed  Google Scholar 

  45. Ishibashi, H., Suzuki, T., Suzuki, S., Moriya, T., Kaneko, C., Takizawa, T., et al. (2003). Sex steroid hormone receptors in human thymoma. The Journal of Clinical Endocrinology and Metabolism, 88(5), 2309–2317. doi:10.1210/jc.2002-021353.

    Article  CAS  PubMed  Google Scholar 

  46. Mimae, T., Tsuta, K., Takahashi, F., Yoshida, A., Kondo, T., Murakami, Y., et al. (2011). Steroid receptor expression in thymomas and thymic carcinomas. Cancer, 117(19), 4396–4405. doi:10.1002/cncr.26061.

    Article  CAS  PubMed  Google Scholar 

  47. Ishibashi, H., Suzuki, T., Suzuki, S., Moriya, T., Kaneko, C., Nakata, T., et al. (2005). Estrogen inhibits cell proliferation through in situ production in human thymoma. Clinical Cancer Research, 11(18), 6495–6504. doi:10.1158/1078-0432.CCR-04-2495.

    Article  CAS  PubMed  Google Scholar 

  48. Brentani, M. M., Butugan, O., Oshima, C. T., Torloni, H., & Paiva, L. J. (1989). Multiple steroid receptors in nasopharyngeal angiofibromas. Laryngoscope, 99(4), 398–401. doi:10.1288/00005537-198904000-00007.

    Article  CAS  PubMed  Google Scholar 

  49. Montag, A. G., Tretiakova, M., & Richardson, M. (2006). Steroid hormone receptor expression in nasopharyngeal angiofibromas. Consistent expression of estrogen receptor beta. American Journal of Clinical Pathology, 125(6), 832–837. doi:10.1309/W5CM-3A3N-H7P4-F5P2.

    Article  CAS  PubMed  Google Scholar 

  50. Xu, B., Hu, P., Wu, Q., Hou, J., Zhang, B., Chen, X., et al. (1999). Relationship between expression of estrogen receptor progesterone receptor and the biological characteristics of nasopharyngeal carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi, 13(8), 347–349.

    CAS  PubMed  Google Scholar 

  51. Mo, L., Kuang, G., Luo, Y., & Yang, R. (2006). Relationship between the expression of estrogen and progestogen receptors in distant metastasis of nasopharyngeal carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi, 20(11), 494–495.

    PubMed  Google Scholar 

  52. Shick, P. C., Riordan, G. P., & Foss, R. D. (1995). Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 80(4), 440–444.

    Article  CAS  PubMed  Google Scholar 

  53. Fahim, L., Weinreb, I., Alexander, C., & Perez Ordonez, B. (2008). Epithelial proliferation in small ducts of salivary cystadenoma resembling atypical ductal hyperplasia of breast. Head and Neck Pathology, 2(3), 213–217. doi:10.1007/s12105-008-0061-6.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Fan, C. Y., Melhem, M. F., Hosal, A. S., Grandis, J. R., & Barnes, E. L. (2001). Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Archives of Otolaryngology - Head and Neck Surgery, 127(9), 1075–1079.

    Article  CAS  PubMed  Google Scholar 

  55. Glas, A. S., Hollema, H., Nap, R. E., & Plukker, J. T. (2002). Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. Cancer, 94(8), 2211–2216. doi:10.1002/cncr.10445.

    Article  CAS  PubMed  Google Scholar 

  56. Ohshiro, K., Rayala, S. K., Williams, M. D., Kumar, R., & El-Naggar, A. K. (2006). Biological role of estrogen receptor beta in salivary gland adenocarcinoma cells. Clinical Cancer Research, 12(20 Pt 1), 5994–5999. doi:10.1158/1078-0432.CCR-06-1251.

    Article  CAS  PubMed  Google Scholar 

  57. Shadaba, A., Gaze, M. N., & Grant, H. R. (1997). The response of adenoid cystic carcinoma to tamoxifen. The Journal of Laryngology and Otology, 111(12), 1186–1189.

    Article  CAS  PubMed  Google Scholar 

  58. Maurizi, M., Ferrandina, G., Almadori, G., Scambia, G., Cadoni, G., D'Agostino, G., et al. (1998). Prognostic significance of methyl-p-hydroxy-phenyllactate-esterase activity in laryngeal squamous cell carcinoma. British Journal of Cancer, 77(8), 1253–1259.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Bianchini, C., Pastore, A., Pelucchi, S., Torreggiani, E., Lambertini, E., Marchesi, E., et al. (2008). Sex hormone receptor levels in laryngeal carcinoma: a comparison between protein and RNA evaluations. European Archives of Oto-Rhino-Laryngology, 265(9), 1089–1094. doi:10.1007/s00405-008-0589-9.

    Article  PubMed  Google Scholar 

  60. Urba, S. G., Carey, T. E., Kudla-Hatch, V., Wolf, G. T., & Forastiere, A. A. (1990). Tamoxifen therapy in patients with recurrent laryngeal squamous carcinoma. Laryngoscope, 100(1), 76–78. doi:10.1288/00005537-199001000-00015.

    Article  CAS  PubMed  Google Scholar 

  61. Lukits, J. (2009). The effect of the microenvironment of head and neck cancers on tumor progression. Magyar Onkologia, 53(1), 51–59. doi:10.1556/MOnkol.53.2009.1.8.

    Article  PubMed  Google Scholar 

  62. Schuller, D. E., Abou-Issa, H., & Parrish, R. (1984). Estrogen and progesterone receptors in head and neck cancer. Archives of Otolaryngology, 110(11), 725–727.

    Article  CAS  PubMed  Google Scholar 

  63. Fisher, R. I., Neifeld, J. P., & Lippman, M. E. (1976). Oestrogen receptors in human malignant melanoma. Lancet, 2(7981), 337–339.

    Article  CAS  PubMed  Google Scholar 

  64. Avril, M. F., Delarue, J. C., & Prade, M. (1985). Estrogen and progesterone receptors in malignant melanoma, benign pigmented nevi and basocellular epithelioma. Pathologie Biologie (Paris), 33(1), 39–44.

    CAS  Google Scholar 

  65. Creagan, E. T., Ingle, J. N., Green, S. J., Ahmann, D. L., & Jiang, N. S. (1980). Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treatment Reports, 64(2–3), 199–201.

    CAS  PubMed  Google Scholar 

  66. Karakousis, C. P., Lopez, R. E., Bhakoo, H. S., Rosen, F., Moore, R., & Carlson, M. (1980). Estrogen and progesterone receptors and tamoxifen in malignant melanoma. Cancer Treatment Reports, 64(6–7), 819–827.

    CAS  PubMed  Google Scholar 

  67. Quencez, E., Blanc, D., Adessi, G., Agache, P., & Laurent, R. (1985). Role of an anti-estrogen, tamoxifen, in the treatment of metastatic malignant melanoma. Annales de Dermatologie et de Vénéréologie, 112(4), 341–346. 349.

    CAS  PubMed  Google Scholar 

  68. Cocconi, G., Bella, M., Calabresi, F., Tonato, M., Canaletti, R., Boni, C., et al. (1992). Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New England Journal of Medicine, 327(8), 516–523. doi:10.1056/NEJM199208203270803.

    Article  CAS  PubMed  Google Scholar 

  69. Bouskine, A., Nebout, M., Mograbi, B., Brucker-Davis, F., Roger, C., & Fenichel, P. (2008). Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology, 149(2), 565–573. doi:10.1210/en.2007-1318.

    Article  CAS  PubMed  Google Scholar 

  70. Pais, V., Leav, I., Lau, K. M., Jiang, Z., & Ho, S. M. (2003). Estrogen receptor-beta expression in human testicular germ cell tumors. Clinical Cancer Research, 9(12), 4475–4482.

    CAS  PubMed  Google Scholar 

  71. Miyamoto, H., Zheng, Y., & Izumi, K. (2012). Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Current Cancer Drug Targets, 12(1), 14–22.

    Article  CAS  PubMed  Google Scholar 

  72. Wei, S., Said-Al-Naief, N., & Hameed, O. (2009). Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Applied Immunohistochemistry and Molecular Morphology, 17(5), 393–402. doi:10.1097/PAI.0b013e31819faa07.

    Article  CAS  PubMed  Google Scholar 

  73. Bolenz, C., Lotan, Y., Ashfaq, R., & Shariat, S. F. (2009). Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. European Urology, 56(6), 1093–1095. doi:10.1016/j.eururo.2009.06.032.

    Article  PubMed  Google Scholar 

  74. Shen, S. S., Smith, C. L., Hsieh, J. T., Yu, J., Kim, I. Y., Jian, W., et al. (2006). Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer, 106(12), 2610–2616. doi:10.1002/cncr.21945.

    Article  CAS  PubMed  Google Scholar 

  75. Dellagrammaticas, D., Bryden, A. A., & Collins, G. N. (2001). Regression of metastatic transitional cell carcinoma in response to tamoxifen. The Journal of Urology, 165(5), 1631.

    Article  CAS  PubMed  Google Scholar 

  76. Ellem, S. J., & Risbridger, G. P. (2010). Aromatase and regulating the estrogen:androgen ratio in the prostate gland. The Journal of Steroid Biochemistry and Molecular Biology, 118(4–5), 246–251. doi:10.1016/j.jsbmb.2009.10.015.

    Article  CAS  PubMed  Google Scholar 

  77. Royuela, M., de Miguel, M. P., Bethencourt, F. R., Sanchez-Chapado, M., Fraile, B., Arenas, M. I., et al. (2001). Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. The Journal of Endocrinology, 168(3), 447–454.

    Article  CAS  PubMed  Google Scholar 

  78. Wolf, R. M., Schneider, S. L., Pontes, J. E., Englander, L., Karr, J. P., Murphy, G. P., et al. (1985). Estrogen and progestin receptors in human prostatic carcinoma. Cancer, 55(10), 2477–2481.

    Article  CAS  PubMed  Google Scholar 

  79. Asgari, M., & Morakabati, A. (2011). Estrogen receptor beta expression in prostate adenocarcinoma. Diagnostic Pathology, 6, 61. doi:10.1186/1746-1596-6-61.

    Article  PubMed Central  PubMed  Google Scholar 

  80. Leav, I., Lau, K. M., Adams, J. Y., McNeal, J. E., Taplin, M. E., Wang, J., et al. (2001). Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. The American Journal of Pathology, 159(1), 79–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  81. Bashirelahi, N., Young, J. D., Shida, K., Yamanaka, H., Ito, Y., & Harada, M. (1983). Androgen, estrogen, and progesterone receptors in peripheral and central zones of human prostate with adenocarcinoma. Urology, 21(5), 530–535.

    Article  CAS  PubMed  Google Scholar 

  82. Spremulli, E., DeSimone, P., & Durant, J. (1982). A phase II study Nolvadex: tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma. American Journal of Clinical Oncology, 5(2), 149–153.

    Article  CAS  PubMed  Google Scholar 

  83. Rades, D., Setter, C., Dahl, O., Schild, S. E., & Noack, F. (2012). The prognostic impact of tumor cell expression of estrogen receptor-alpha, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer, 118(1), 157–163. doi:10.1002/cncr.26282.

    Article  CAS  PubMed  Google Scholar 

  84. Mauro, L. V., Dalurzo, M., Carlini, M. J., Smith, D., Nunez, M., Simian, M., et al. (2010). Estrogen receptor beta and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer. Oncology Reports, 24(5), 1331–1338.

    PubMed  Google Scholar 

  85. Sun, H. B., Zheng, Y., Ou, W., Fang, Q., Li, P., Ye, X., et al. (2011). Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer. The Annals of Thoracic Surgery, 91(5), 1562–1567. doi:10.1016/j.athoracsur.2011.02.001.

    Article  PubMed  Google Scholar 

  86. Shen, H., Yuan, Y., Sun, J., Gao, W., & Shu, Y. Q. (2010). Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomedicine and Pharmacotherapy, 64(2), 88–92. doi:10.1016/j.biopha.2009.06.010.

    Article  CAS  PubMed  Google Scholar 

  87. Perez, E. A., Gandara, D. R., Edelman, M. J., O'Donnell, R., Lauder, I. J., & DeGregorio, M. (2003). Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Investigation, 21(1), 1–6.

    Article  CAS  PubMed  Google Scholar 

  88. Lara, P. N., Jr., Gandara, D. R., Longmate, J., Gumerlock, P. H., Lau, D. H., Edelman, M. J., et al. (2001). Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemotherapy and Pharmacology, 48(1), 22–28.

    Article  CAS  PubMed  Google Scholar 

  89. Chen, Y., Perng, R. P., Yang, K. Y., Lin, W. C., Wu, H. W., Tsai, C. M., et al. (2000). Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung Cancer, 29(2), 139–146.

    Article  CAS  PubMed  Google Scholar 

  90. Figueredo, A., Arnold, A., Goodyear, M., Findlay, B., Neville, A., Normandeau, R., et al. (1990). Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer, 65(9), 1895–1902.

    Article  CAS  PubMed  Google Scholar 

  91. Chen, Y. M., Perng, R. P., Yang, K. Y., Wu, H. W., Lin, W. C., Liu, J. M., et al. (2000). Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer. Zhonghua Yi Xue Za Zhi (Taipei), 63(8), 605–611.

    CAS  Google Scholar 

  92. McClay, E. F., Bogart, J., Herndon, J. E., Watson, D., 2nd, Evans, L., Seagren, S. L., et al. (2005). A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B study (9235). American Journal of Clinical Oncology, 28(1), 81–90.

    Article  CAS  PubMed  Google Scholar 

  93. Harrison, J. D., Morris, D. L., Ellis, I. O., Jones, J. A., & Jackson, I. (1989). The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma. Cancer, 64(5), 1007–1010.

    Article  CAS  PubMed  Google Scholar 

  94. Li, D. Q., Pan, L. H., & Shao, Z. M. (2004). Inhibitory effects of mifepristone on the growth of human gastric cancer cell line MKN-45 in vitro and in vivo. Chinese Medical Sciences Journal, 19(4), 237–242.

    CAS  PubMed  Google Scholar 

  95. Matsuyama, S., Ohkura, Y., Eguchi, H., Kobayashi, Y., Akagi, K., Uchida, K., et al. (2002). Estrogen receptor beta is expressed in human stomach adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 128(6), 319–324. doi:10.1007/s00432-002-0336-3.

    Article  CAS  PubMed  Google Scholar 

  96. Ryu, W. S., Kim, J. H., Jang, Y. J., Park, S. S., Um, J. W., Park, S. H., et al. (2012). Expression of estrogen receptors in gastric cancer and their clinical significance. Journal of Surgical Oncology, 106(4), 456–461. doi:10.1002/jso.23097.

    Article  CAS  PubMed  Google Scholar 

  97. Lamy, R., Conroy, T., Brunaud, L., & Bresler, L. (2001). Tamoxifen for metastatic pancreatic adenocarcinoma: a complete response. Gastroentérologie Clinique et Biologique, 25(10), 912–913.

    CAS  PubMed  Google Scholar 

  98. Tomao, S., Romiti, A., Massidda, B., Ionta, M. T., Farris, A., Zullo, A., et al. (2002). A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer. Anticancer Research, 22(4), 2361–2364.

    CAS  PubMed  Google Scholar 

  99. Eckel, F., Lersch, C., Lippl, F., Assmann, G., & Schulte-Frohlinde, E. (2000). Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer. Journal of Experimental & Clinical Cancer Research, 19(3), 295–300.

    CAS  Google Scholar 

  100. Sun, M., Estrov, Z., Ji, Y., Coombes, K. R., Harris, D. H., & Kurzrock, R. (2008). Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Molecular Cancer Therapeutics, 7(3), 464–473. doi:10.1158/1535-7163.MCT-07-2272.

    Article  CAS  PubMed  Google Scholar 

  101. Chua, T. C., Yao, P., Akther, J., Young, L., Bao, S., Samaraweera, U., et al. (2009). Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. Pathology and Oncology Research, 15(4), 671–678. doi:10.1007/s12253-009-9170-0.

    Article  CAS  PubMed  Google Scholar 

  102. Pass, H. I., Temeck, B. K., Kranda, K., Thomas, G., Russo, A., Smith, P., et al. (1997). Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Annals of Surgical Oncology, 4(8), 628–633.

    Article  CAS  PubMed  Google Scholar 

  103. Kwasniewska, A., Postawski, K., Gozdzicka-Jozefiak, A., Kwasniewski, W., Grywalska, E., Zdunek, M., et al. (2011). Estrogen and progesterone receptor expression in HPV-positive and HPV-negative cervical carcinomas. Oncology Reports, 26(1), 153–160. doi:10.3892/or.2011.1256.

    PubMed  Google Scholar 

  104. Bigler, L. R., Tate Thigpen, J., Blessing, J. A., Fiorica, J., & Monk, B. J. (2004). Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. International Journal of Gynecological Cancer, 14(5), 871–874. doi:10.1111/j.1048-891X.2004.14523.x.

    Article  CAS  PubMed  Google Scholar 

  105. Markova, I., Pilka, R., Duskova, M., Zapletalova, J., & Kudela, M. (2010). Prognostic significance of clinic pathological and selected immunohistochemical factors in endometrial cancer. Ceská Gynekologie, 75(3), 193–199.

    CAS  PubMed  Google Scholar 

  106. Covens, A. L., Filiaci, V., Gersell, D., Lutman, C. V., Bonebrake, A., & Lee, Y. C. (2011). Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology, 120(2), 185–188. doi:10.1016/j.ygyno.2010.10.015.

    Article  CAS  PubMed  Google Scholar 

  107. Xie, Y., Wang, Y. L., Yu, L., Hu, Q., Ji, L., Zhang, Y., et al. (2011). Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. The Journal of Steroid Biochemistry and Molecular Biology, 126(3–5), 113–120. doi:10.1016/j.jsbmb.2010.12.006.

    Article  CAS  PubMed  Google Scholar 

  108. Ramondetta, L. M., Johnson, A. J., Sun, C. C., Atkinson, N., Smith, J. A., Jung, M. S., et al. (2009). Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer, 115(9), 1867–1874. doi:10.1002/cncr.24197.

    Article  CAS  PubMed  Google Scholar 

  109. Sinn, B. V., Darb-Esfahani, S., Wirtz, R. M., Budczies, J., Sehouli, J., Chekerov, R., et al. (2011). Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. Histopathology, 59(5), 918–927. doi:10.1111/j.1365-2559.2011.04028.x.

    Article  PubMed  Google Scholar 

  110. De Stefano, I., Zannoni, G. F., Prisco, M. G., Fagotti, A., Tortorella, L., Vizzielli, G., et al. (2011). Cytoplasmic expression of estrogen receptor beta (ERbeta) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecologic Oncology, 122(3), 573–579. doi:10.1016/j.ygyno.2011.05.025.

    Article  PubMed  CAS  Google Scholar 

  111. Farinola, M. A., Gown, A. M., Judson, K., Ronnett, B. M., Barry, T. S., Movahedi-Lankarani, S., et al. (2007). Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. International Journal of Gynecological Pathology, 26(4), 375–382. doi:10.1097/pgp.0b013e31805c0d99.

    Article  PubMed  Google Scholar 

  112. Makar, A. P. (2000). Hormone therapy in epithelial ovarian cancer. Endocrine-Related Cancer, 7(2), 85–93.

    Article  CAS  PubMed  Google Scholar 

  113. Qi, J. P., Yang, Y. L., Zhu, H., Wang, J., Jia, Y., Liu, N., et al. (2012). Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer (Auckl.), 6, 1–8. doi:10.4137/BCBCR.S8323.

    Google Scholar 

  114. Ng, C. H., Pathy, N. B., Taib, N. A., Mun, K. S., Rhodes, A., & Yip, C. H. (2012). The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact. Asian Pacific Journal of Cancer Prevention, 13(4), 1111–1113.

    Article  PubMed  Google Scholar 

  115. Smith, I. E., & Dowsett, M. (2003). Aromatase inhibitors in breast cancer. New England Journal of Medicine, 348(24), 2431–2442. doi:10.1056/NEJMra023246.

    Article  CAS  PubMed  Google Scholar 

  116. Holst, F., Stahl, P. R., Ruiz, C., Hellwinkel, O., Jehan, Z., Wendland, M., et al. (2007). Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics, 39(5), 655–660. doi:10.1038/ng2006.

    Article  CAS  PubMed  Google Scholar 

  117. Ooi, A., Inokuchi, M., Harada, S., Inazawa, J., Tajiri, R., Kitamura, S. S., et al. (2012). Gene amplification of ESR1 in breast cancers—fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. The Journal of Pathology, 227(1), 8–16. doi:10.1002/path.3974.

    Article  CAS  PubMed  Google Scholar 

  118. Robinson, D. R., Wu, Y. M., Vats, P., Su, F., Lonigro, R. J., Cao, X., et al. (2013). Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nature Genetics, 45(12), 1446–1451. doi:10.1038/ng.2823.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  119. Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., et al. (2013). ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics, 45(12), 1439–1445. doi:10.1038/ng.2822.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  120. Baselga, J., Campone, M., Piccart, M., Burris, H. A., 3rd, Rugo, H. S., Sahmoud, T., et al. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine, 366(6), 520–529. doi:10.1056/NEJMoa1109653.

    Article  CAS  PubMed  Google Scholar 

  121. Wheler, J. J., Moulder, S. L., Naing, A., Janku, F., Piha-Paul, S. A., Falchook, G. S., et al. (2014). Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget, 5(10), 3029–3038.

    Article  PubMed Central  PubMed  Google Scholar 

  122. Shen, X. C., Gu, C. X., Qiu, Y. Q., Du, C. J., Fu, Y. B., & Wu, J. J. (2009). Estrogen receptor expression in adrenocortical carcinoma. Journal of Zhejiang University. Science. B, 10(1), 1–6. doi:10.1631/jzus.B0820072.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  123. Montanaro, D., Maggiolini, M., Recchia, A. G., Sirianni, R., Aquila, S., Barzon, L., et al. (2005). Antiestrogens upregulate estrogen receptor beta expression and inhibit adrenocortical H295R cell proliferation. Journal of Molecular Endocrinology, 35(2), 245–256. doi:10.1677/jme.1.01806.

    Article  CAS  PubMed  Google Scholar 

  124. Assimakopoulou, M., Sotiropoulou-Bonikou, G., Maraziotis, T., & Varakis, J. (1998). Does sex steroid receptor status have any prognostic or predictive significance in brain astrocytic tumors? Clinical Neuropathology, 17(1), 27–34.

    CAS  PubMed  Google Scholar 

  125. Rogers, G. S., Flowers, J. L., Pollack, S. V., & McCarty, K. S., Jr. (1988). Determination of sex steroid receptor in human basal cell carcinoma. Journal of the American Academy of Dermatology, 18(5 Pt 1), 1039–1043.

    Article  CAS  PubMed  Google Scholar 

  126. Santos, G. A., Cunha, I. W., Rocha, R. M., Mello, C. A., Guimaraes, G. C., Fregnani, J. H., et al. (2010). Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. Bioscience Trends, 4(1), 25–30.

    CAS  PubMed  Google Scholar 

  127. Ishizuka, M., Hatori, M., Dohi, O., Suzuki, T., Miki, Y., Tazawa, C., et al. (2006). Expression profiles of sex steroid receptors in desmoid tumors. Tohoku Journal of Experimental Medicine, 210(3), 189–198.

    Article  CAS  PubMed  Google Scholar 

  128. Halevy, A., Samuk, I., Halpern, Z., Copel, L., Sandbank, J., & Ziv, Y. (2010). Mifepristone (RU486), a pure antiprogesterone drug, in combination with vinblastine for the treatment of progesterone receptor-positive desmoid tumor. Techniques in Coloproctology, 14(3), 265–267. doi:10.1007/s10151-010-0591-2.

    Article  CAS  PubMed  Google Scholar 

  129. Bocale, D., Rotelli, M. T., Cavallini, A., & Altomare, D. F. (2011). Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Disease, 13(12), e388–e395. doi:10.1111/j.1463-1318.2011.02758.x.

    Article  CAS  PubMed  Google Scholar 

  130. Debled, M., Le Loarer, F., Callonnec, F., Soubeyran, I., Cambon-Michot, C., Dujardin, F., et al. (2012). Complete response to exemestane in a patient with a desmoid tumor. Future Oncology, 8(4), 483–486. doi:10.2217/fon.12.24.

    Article  CAS  PubMed  Google Scholar 

  131. Brodsky, S. V., Gimenez, C., Ghosh, C., Melamed, M., & Ramaswamy, G. (2006). Estrogen and progesterone receptors expression in gastrointestinal stromal tumors and intramural gastrointestinal leiomyomas. International Journal of Gastrointestinal Cancer, 37(4), 129–132. doi:10.1007/s12029-007-9003-x.

    PubMed  Google Scholar 

  132. Patel, S., DiBiase, S., Meisenberg, B., Flannery, T., Patel, A., Dhople, A., et al. (2012). Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. International Journal of Radiation Oncology, Biology, and Physics, 82(2), 739–742. doi:10.1016/j.ijrobp.2010.12.053.

    Article  CAS  Google Scholar 

  133. Christeff, N., Winter, C., Gharakhanian, S., Thobie, N., Wirbel, E., Costagliola, D., et al. (1995). Differences in androgens of HIV positive patients with and without Kaposi sarcoma. Journal of Clinical Pathology, 48(6), 513–518.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  134. Ziegler, J. L., Katongole-Mbidde, E., Wabinga, H., & Dollbaum, C. M. (1995). Absence of sex-hormone receptors in Kaposi's sarcoma. Lancet, 345(8954), 925.

    Article  CAS  PubMed  Google Scholar 

  135. Lunardi-Iskandar, Y., Bryant, J. L., Zeman, R. A., Lam, V. H., Samaniego, F., Besnier, J. M., et al. (1995). Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature, 375(6526), 64–68. doi:10.1038/375064a0.

    Article  CAS  PubMed  Google Scholar 

  136. Gill, P. S., Lunardi-Ishkandar, Y., Louie, S., Tulpule, A., Zheng, T., Espina, B. M., et al. (1996). The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. New England Journal of Medicine, 335(17), 1261–1269. doi:10.1056/NEJM199610243351702.

    Article  CAS  PubMed  Google Scholar 

  137. Hong, A., & Leigh, B. R. (2002). Antiproliferative properties of toremifene on AIDS-related Kaposi's sarcoma cells. Chemotherapy, 48(5), 238–243.

    Article  CAS  PubMed  Google Scholar 

  138. Leitao, M. M., Soslow, R. A., Nonaka, D., Olshen, A. B., Aghajanian, C., Sabbatini, P., et al. (2004). Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer, 101(6), 1455–1462. doi:10.1002/cncr.20521.

    Article  CAS  PubMed  Google Scholar 

  139. Donnez, J., Tatarchuk, T. F., Bouchard, P., Puscasiu, L., Zakharenko, N. F., Ivanova, T., et al. (2012). Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine, 366(5), 409–420. doi:10.1056/NEJMoa1103182.

    Article  CAS  PubMed  Google Scholar 

  140. Baytur, Y. B., Ozbilgin, K., Cilaker, S., Lacin, S., Kurtul, O., Oruc, S., et al. (2007). A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 135(1), 94–103. doi:10.1016/j.ejogrb.2006.07.042.

    Article  CAS  PubMed  Google Scholar 

  141. Check, J. H., Dix, E., Cohen, R., Check, D., & Wilson, C. (2010). Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Research, 30(2), 623–628.

    CAS  PubMed  Google Scholar 

  142. Vaquero, J., Marcos, M. L., Martinez, R., & Bravo, G. (1983). Estrogen- and progesterone-receptor proteins in intracranial tumors. Surgical Neurology, 19(1), 11–13.

    Article  CAS  PubMed  Google Scholar 

  143. Liu, J., Le, X., & Li, Y. (1998). Pathological study of ER and PR in osteosarcoma. Zhonghua Wai Ke Za Zhi, 36(4), 245–246. 245.

    CAS  PubMed  Google Scholar 

  144. Slootweg, M. C., Swolin, D., Netelenbos, J. C., Isaksson, O. G., & Ohlsson, C. (1997). Estrogen enhances growth hormone receptor expression and growth hormone action in rat osteosarcoma cells and human osteoblast-like cells. The Journal of Endocrinology, 155(1), 159–164.

    Article  CAS  PubMed  Google Scholar 

  145. Dohi, O., Hatori, M., Suzuki, T., Ono, K., Hosaka, M., Akahira, J., et al. (2008). Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. Cancer Science, 99(3), 518–523. doi:10.1111/j.1349-7006.2007.00673.x.

    Article  CAS  PubMed  Google Scholar 

  146. Rajabalian, S., Hajializadeh, Z., Pooraboli, I., Jangi-Aghdam, H., & Badinloo, M. (2010). Establishment, characterization, and drug sensitivity of a new Ewing sarcoma cell line (SS-ES-1). Journal of Pediatric Hematology/Oncology, 32(8), e331–e337. doi:10.1097/MPH.0b013e3181ee4d16.

    Article  CAS  PubMed  Google Scholar 

  147. DuBois, S. G., Perez-Atayde, A. R., McLean, T. W., & Grier, H. E. (2008). Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases. Journal of Pediatric Hematology/Oncology, 30(9), 716–718. doi:10.1097/MPH.0b013e318175895f.

    Article  PubMed  Google Scholar 

  148. Hurteau, J. A., Brady, M. F., Darcy, K. M., McGuire, W. P., Edmonds, P., Pearl, M. L., et al. (2010). Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecologic Oncology, 119(3), 444–450. doi:10.1016/j.ygyno.2010.08.002.

    Article  CAS  PubMed  Google Scholar 

  149. Freeman, S. A., & Modesitt, S. C. (2006). Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. Gynecologic Oncology, 103(2), 755–758. doi:10.1016/j.ygyno.2006.06.022.

    Article  PubMed  Google Scholar 

  150. Singh, P. B., Matanhelia, S. S., & Martin, F. L. (2008). A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. European Journal of Cancer, 44(7), 928–936. doi:10.1016/j.ejca.2008.02.051.

    Article  CAS  PubMed  Google Scholar 

  151. Langner, C., Ratschek, M., Rehak, P., Schips, L., & Zigeuner, R. (2004). Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. The Journal of Urology, 171(2 Pt 1), 611–614. doi:10.1097/01.ju.0000108040.14303.c2.

    CAS  PubMed  Google Scholar 

  152. Zeng, Q., Chen, G., Vlantis, A., Tse, G., & van Hasselt, C. (2008). The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. The Journal of Pathology, 214(4), 425–433. doi:10.1002/path.2297.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology-Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA

    J. Munoz

  2. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    J. Wheler

  3. Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA, USA

    R. Kurzrock

Authors
  1. J. Munoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Wheler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Kurzrock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Munoz.

Additional information

JM and JW share first authorship.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Munoz, J., Wheler, J. & Kurzrock, R. Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. Cancer Metastasis Rev 34, 547–561 (2015). https://doi.org/10.1007/s10555-014-9543-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-014-9543-z

Keywords

Search

Navigation